IQVIA (NYSE:IQV) Upgraded by TD Cowen to Buy Rating

TD Cowen upgraded shares of IQVIA (NYSE:IQV) from a hold rating to a buy rating in a research report released on Monday morning, Marketbeat reports. TD Cowen currently has $213.00 target price on the medical research company’s stock, up from their previous target price of $174.00.

Several other research firms have also recently weighed in on IQV. UBS Group cut their target price on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Royal Bank Of Canada began coverage on IQVIA in a research note on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price objective on the stock. Citigroup dropped their target price on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a report on Friday, February 6th. Stifel Nicolaus decreased their price target on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Finally, Mizuho set a $215.00 price objective on shares of IQVIA in a research note on Monday, February 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $229.13.

IQVIA Stock Up 2.5%

Shares of NYSE IQV opened at $178.87 on Monday. The stock has a market capitalization of $30.35 billion, a P/E ratio of 22.76, a PEG ratio of 1.68 and a beta of 1.40. The stock’s fifty day moving average is $206.26 and its 200 day moving average is $207.53. IQVIA has a 52 week low of $134.65 and a 52 week high of $247.04. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The firm had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the prior year, the company posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Sell-side analysts forecast that IQVIA will post 10.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in IQV. Corient Private Wealth LLC grew its holdings in IQVIA by 18.4% during the 4th quarter. Corient Private Wealth LLC now owns 15,358 shares of the medical research company’s stock worth $3,462,000 after acquiring an additional 2,383 shares during the last quarter. Pure Financial Advisors LLC lifted its holdings in shares of IQVIA by 7.2% during the fourth quarter. Pure Financial Advisors LLC now owns 11,731 shares of the medical research company’s stock worth $2,644,000 after purchasing an additional 792 shares during the period. Rehmann Capital Advisory Group lifted its holdings in shares of IQVIA by 32.6% during the fourth quarter. Rehmann Capital Advisory Group now owns 2,196 shares of the medical research company’s stock worth $497,000 after purchasing an additional 540 shares during the period. Tulsa Wealth Advisors INC bought a new stake in shares of IQVIA in the fourth quarter worth $1,313,000. Finally, Reflection Asset Management acquired a new stake in IQVIA in the fourth quarter valued at $38,000. Institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.